Table 1. Descriptive data of the study cohort and the datasets used to develop the ERSPC and PCPT risk calculators.
| Study cohort | ERSPC | PCPT | ||||
|---|---|---|---|---|---|---|
| Number | 495 | 3624 | 5519 | |||
| Age, mean±s.d., (year) | 66.1±9.2 | 65.5±5.4 | NA | |||
| Age, No. (%) | ||||||
| <55 years | 50 | (10.1) | 0 | (0) | 0 | (0) |
| 55–59 years | 56 | (11.3) | 708 | (19.5) | 38 | (0.7) |
| 60–64 years | 102 | (20.6) | 919 | (25.4) | 1143 | (20.7) |
| 65–69 years | 100 | (20.2) | 1138 | (31.4) | 1741 | (31.5) |
| ≥70 years | 187 | (37.8) | 859 | (23.7) | 2597 | (47.1) |
| Family history, No. (%) | 3 | (0.006) | 304 | (8.4) | 920 | (16.7) |
| 5-α reductase, No. (%) | 17 | (3.4) | NA | NA | 0 | (0) |
| PSA level, median (25–75 percentile) (ng ml−1) | 10.2 | (6.76–18.53) | 4.3 | (3.1–6.4) | 1.5 | |
| PSA level, No. (%) | ||||||
| ≤4 ng ml−1 | 36 | (7.3) | 1613 | (44.5) | 4888 | (88.6) |
| >4 ng ml−1 | 459 | (92.7) | 2011 | (55.5) | 631 | (11.4) |
| Volume, median (25–75 percentile) (ml) | 42.8 | (30.5–61) | 41 | (32–55) | NA | |
| Abnormal DRE, No. (%) | 169 | (34.14) | 1284 | (35.4) | 551 | (10.0) |
| Abnormal TRUS, No. (%) | 193 | (38.99) | 1233 | (34.0) | NA | |
| Prior biopsy, No. (%) | 93 | (18.79) | NA | 646 | (11.7) | |
| Prostate cancer, No. (%) | 142 | (28.69) | 893 | (24.6) | 1211 | (21.9) |
| High grade cancer (Gleason >6), No. (%) | 96 | (19.39) | NA | 257 | (4.7) | |
Abbreviations: DRE, digital rectal examination; ERSPC, European Randomized Study of Screening for Prostate Cancer; NA, not available; PCPT, Prostate Cancer Prevention Trial; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.